Semisynthetic neoclerodanes as kappa opioid receptor probes

被引:23
|
作者
Lovell, Kimberly M. [1 ]
Vasiljevik, Tamara [1 ]
Araya, Juan J. [1 ]
Lozama, Anthony [2 ]
Prevatt-Smith, Katherine M. [1 ]
Day, Victor W. [1 ]
Dersch, Christina M. [3 ]
Rothman, Richard B. [3 ]
Butelman, Eduardo R. [4 ]
Kreek, Mary Jeanne [4 ]
Prisinzano, Thomas E. [1 ]
机构
[1] Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA
[2] Univ Iowa, Div Med & Nat Prod Chem, Iowa City, IA 52242 USA
[3] NIDA, Clin Psychopharmacol Sect, IRP, DHHS, Baltimore, MD 21224 USA
[4] Rockefeller Univ, Lab Biol Addict Dis, New York, NY USA
基金
美国国家科学基金会;
关键词
Natural product; Salvinorin A; Salvia divinorum; Kappa opioid receptor; Hallucinogen; Furan; SALVINORIN-A; SALVIA-DIVINORUM; NATURAL-PRODUCTS; LIGANDS; AGONIST; TRANSFORMATIONS; IDENTIFICATION; HALLUCINOGEN; ANTAGONISTS; DITERPENES;
D O I
10.1016/j.bmc.2012.02.040
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Modification of the furan ring of salvinorin A (1), the main active component of Salvia divinorum, has resulted in novel neoclerodane diterpenes with opioid receptor affinity and activity. Conversion of the furan ring to an aldehyde at the C-12 position (5) has allowed for the synthesis of analogues with new carbon-carbon bonds at that position. Previous methods for forming these bonds, such as Grignard and Stille conditions, have met with limited success. We report a palladium catalyzed Liebeskind-Srogl cross-coupling reaction of a thioester and a boronic acid that occurs at neutral pH and ambient temperature to produce ketone analogs at C-12. To the best of our knowledge, this is the first reported usage of the Liebeskind-Srogl reaction to diversify a natural product scaffold. We also describe a one-step protocol for the conversion of 1 to 12-epi-1 (3) through microwave irradiation. Previously, this synthetically challenging process has required multiple steps. Additionally, we report in this study that alkene 9 and aromatic analogues 12, 19, 23, 25, and 26 were discovered to retain affinity and selectivity at kappa opioid receptors (KOP). Finally, we report that the furan-2-yl analog of 1 (31) has similar affinity to 1. Collectively, these findings suggest that different aromatic groups appended directly to the decalin core may be well tolerated by KOP receptors, and may generate further ligands with affinity and activity at KOP receptors. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3100 / 3110
页数:11
相关论文
共 50 条
  • [21] Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial
    Mendelson, John E.
    Coyle, Jeremy R.
    Lopez, Juan Carlos
    Baggott, Matthew J.
    Flower, Keith
    Everhart, E. Thomas
    Munro, Thomas A.
    Galloway, Gantt P.
    Cohen, Bruce M.
    PSYCHOPHARMACOLOGY, 2011, 214 (04) : 933 - 939
  • [22] Psychotomimetic Effects of Kappa Opioid Receptor Agonists
    White, Kate L.
    Roth, Bryan L.
    BIOLOGICAL PSYCHIATRY, 2012, 72 (10) : 797 - 798
  • [23] Signaling underlying kappa opioid receptor-mediated behaviors in rodents
    Liu-Chen, Lee-Yuan
    Huang, Peng
    FRONTIERS IN NEUROSCIENCE, 2022, 16
  • [24] Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents
    Walentiny, D. Matthew
    Vann, Robert E.
    Warner, Jonathan A.
    King, Lindsey S.
    Seltzman, Herbert H.
    Navarro, Hernan A.
    Twine, Charles E., Jr.
    Thomas, Brian F.
    Gilliam, Anne F.
    Gilmour, Brian P.
    Carroll, F. Ivy
    Wiley, Jenny L.
    PSYCHOPHARMACOLOGY, 2010, 210 (02) : 275 - 284
  • [25] Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum
    Johnson, Matthew W.
    MacLean, Katherine A.
    Reissig, Chad J.
    Prisinzano, Thomas E.
    Griffiths, Roland R.
    DRUG AND ALCOHOL DEPENDENCE, 2011, 115 (1-2) : 150 - 155
  • [26] Kinase cascades and ligand-directed signaling at the kappa opioid receptor
    Bruchas, Michael R.
    Chavkin, Charles
    PSYCHOPHARMACOLOGY, 2010, 210 (02) : 137 - 147
  • [27] ISThe Therapeutic Potential of Novel Kappa Opioid Receptor-based Treatments
    Mercadante, Sebastiano
    Romualdi, Patrizia
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (12) : 2012 - 2020
  • [28] A review of the kappa opioid receptor system in opioid use
    Cayir, Salih
    Zhornitsky, Simon
    Barzegary, Alireza
    Sotomayor-Carreno, Esteban
    Sarfo-Ansah, Wonder
    Funaro, Melissa C.
    Matuskey, David
    Angarita, Gustavo
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2024, 162
  • [29] In Vitro, In Vivo and In Silico Characterization of a Novel Kappa-Opioid Receptor Antagonist
    Puls, Kristina
    Olive-Marti, Aina-Leonor
    Pach, Szymon
    Pinter, Birgit
    Erli, Filippo
    Wolber, Gerhard
    Spetea, Mariana
    PHARMACEUTICALS, 2022, 15 (06)
  • [30] Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders (vol 6, 190, 2015)
    Butelman, Eduardo R.
    Kreek, Mary Jeanne
    FRONTIERS IN PHARMACOLOGY, 2015, 6